Search
Ansuvimab
go.drugbank.com/drugs/DB16385ApprovedHowever, to date, the most successful method appears to be the development of monoclonal antibodies (mAbs) against the GP<sub>1,2</sub> surface glycoprotein, as evidenced by the previously approved INMAZEB … [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.
Diethylamino hydroxybenzoyl hexyl benzoate
go.drugbank.com/drugs/DB11269ApprovedDiethylamino hydroxybenzoyl hexyl benzoate is a UV filter with high absorption in the UV-A range. Minimizing the overexposure of human skin to ultraviolet radiation that may lead to acute and chronic photodamage, diethylamino hydroxybenz...
Mixtures: D-one By Tamdoan Bb Light, D-one By Tamdoan Bb MediumForeskin fibroblast (neonatal)
go.drugbank.com/drugs/DB10770ApprovedInterestingly, it has been shown that human foreskin cells possess immunosuppressive properties, which are mediated by other processes than that reported for bone marrow/stromal stem cells [A32655].
Benzquinamide
go.drugbank.com/drugs/DB00767ApprovedWithdrawnThe mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.
Cinoxacin
go.drugbank.com/drugs/DB00827ApprovedWithdrawnSynthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Chloramphenicol
go.drugbank.com/drugs/DB00446ApprovedInvestigationalVet approvedWithdrawnAn antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. … It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic.
Quercus rubra pollen
go.drugbank.com/drugs/DB10481ApprovedQuercus rubra pollen is the pollen of the Quercus rubra plant. Quercus rubra pollen is mainly used in allergenic testing.
Mixtures: 5-oak Mix, Blackjack/bur/post/red/white PollenDiroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigationalDiroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225] … This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure.
Revefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigational[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]
Trastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigational[A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]